国药现代：法莫替丁注射液通过仿制药质量和疗效一致性评价

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Famotidine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - Guoyao Modern's subsidiary has been granted a supplementary application approval for Famotidine injection [1] - Famotidine is an H2 receptor antagonist used for treating upper gastrointestinal bleeding caused by various factors, excluding tumors and esophageal or gastric varices [1] - The approval indicates the company's capability to produce a drug that meets regulatory standards for quality and efficacy [1]